NCT04815395

Brief Summary

The main aim of the present study is to investigate whether oxytocin (24IU) via different routes have divergent effects on attention control in a social-emotional saccade/antisaccade eye-tracking paradigm.

Trial Health

87
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
151

participants targeted

Target at P75+ for not_applicable healthy

Timeline
Completed

Started Dec 2017

Longer than P75 for not_applicable healthy

Geographic Reach
1 country

1 active site

Status
completed

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Start

First participant enrolled

December 19, 2017

Completed
3 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

January 1, 2021

Completed
Same day until next milestone

Study Completion

Last participant's last visit for all outcomes

January 1, 2021

Completed
3 months until next milestone

First Submitted

Initial submission to the registry

March 22, 2021

Completed
3 days until next milestone

First Posted

Study publicly available on registry

March 25, 2021

Completed
Last Updated

March 25, 2021

Status Verified

March 1, 2021

Enrollment Period

3 years

First QC Date

March 22, 2021

Last Update Submit

March 22, 2021

Conditions

Healthy

Keywords

Antisaccade taskAttention controlOxytocinEye-tracking

Outcome Measures

Primary Outcomes (2)

  • Differential effects of intranasal and oral oxytocin administration on saccade/antisaccade latencies towards social (facial) versus non-social (shape) stimuli

    Comparison between social-specific saccade/antisaccade latencies (in milliseconds) between the intranasal and oral oxytocin and placebo treatment conditions

    45 minutes - 100 minutes after treatment

  • Differential effects of intranasal and oral oxytocin administration on error rates of saccade/antisaccade for social (facial) versus non-social (shape) stimuli

    Comparison between social-specific error rates of saccade/antisaccade between the intranasal and oral oxytocin and placebo treatment conditions.

    45 minutes - 100 minutes after treatment

Secondary Outcomes (2)

  • Emotion-specific effects of intranasal and oral oxytocin administration on saccade/antisaccade latencies towards the separate facial emotions

    45 minutes - 100 minutes after treatment

  • Emotion-specific effects of intranasal and oral oxytocin administration on saccade/antisaccade error rates for the separate facial emotions

    45 minutes - 100 minutes after treatment

Study Arms (3)

Oral Oxytocin

EXPERIMENTAL

Oxytocin (24IU) orally

Drug: Oxytocin

Intranasal Oxytocin

EXPERIMENTAL

Oxytocin (24IU) intranasally

Drug: Oxytocin

Oral Placebo

PLACEBO COMPARATOR

Placebo orally

Drug: Placebo

Interventions

OxytocinDRUG

Administration of oxytocin (24IU) orally

Oral Oxytocin
PlaceboDRUG

Administration of placebo orally

Oral Placebo

Eligibility Criteria

Age18 Years - 30 Years
Sexmale
Healthy VolunteersYes
Age GroupsAdult (18-64)

You may qualify if:

  • Male, healthy participants
  • Non smokers

You may not qualify if:

  • Previous or current medical, psychiatric, neurological disorder
  • Regular medication
  • Use of any psychoactive substances in the 24 hours before experiment
  • Contra-indications for eye-tracking data acquisition

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

University of Electronic Science and Technology of China(UESTC)

Chengdu, Sichuan, 611731, China

Location

MeSH Terms

Interventions

Oxytocin

Intervention Hierarchy (Ancestors)

Pituitary Hormones, PosteriorPituitary HormonesPeptide HormonesHormonesHormones, Hormone Substitutes, and Hormone AntagonistsPeptidesAmino Acids, Peptides, and Proteins

Study Officials

  • Keith Kendrick, PhD

    University of Electronic Science and Technology of China (UESTC)

    PRINCIPAL INVESTIGATOR

Study Design

Study Type
interventional
Phase
not applicable
Allocation
RANDOMIZED
Masking
TRIPLE
Who Masked
PARTICIPANT, INVESTIGATOR, OUTCOMES ASSESSOR
Purpose
BASIC SCIENCE
Intervention Model
PARALLEL
Model Details: Between-subject randomized placebo-controlled double-blind pharmacological eye-tracking design
Sponsor Type
OTHER
Responsible Party
PRINCIPAL INVESTIGATOR
PI Title
Professor

Study Record Dates

First Submitted

March 22, 2021

First Posted

March 25, 2021

Study Start

December 19, 2017

Primary Completion

January 1, 2021

Study Completion

January 1, 2021

Last Updated

March 25, 2021

Record last verified: 2021-03

Data Sharing

IPD Sharing
Will not share

Locations

CN(1)